ALS Limited (ASX:ALQ): FY26 Earnings, Laboratory Operations and Sector Developments

Aditi Sarkar

26 October 2026 07:38 PM AEDT

ALS Limited (ASX:ALQ): FY26 Earnings, Laboratory Operations and Sector Developments

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

ALS Limited (ASX:ALQ) reported FY26 revenue of AUD 3.32bn, up 10.7% YoY.
Underlying EBIT increased 19.3% YoY to AUD 599.0mn, with an 18.0% margin.
Commodities revenue rose 18.8% YoY to AUD 1.29bn, led by mineral testing activity.
FY26 statutory NPAT reached AUD 318.7mn; net debt declined to AUD 1.07bn.

ALS Limited provides laboratory testing, inspection and technical services to customers across commodities, environmental, food and pharmaceutical markets. After reporting higher FY26 revenue and earnings, ALS Limited (ASX:ALQ) shares closed at AUD 19.99 on 26 October 2026. The company’s latest annual results highlight differing trading conditions across its Commodities and Life Sciences divisions, alongside investment in laboratory capacity and further work on operating efficiency.

Company Business

ALS Limited (ASX:ALQ) operates a network of laboratories that analyse samples, verify product characteristics and provide technical information to industrial, commercial and government customers. Its Commodities division serves mineral exploration, mining, coal and oil-related markets, while Life Sciences encompasses environmental, food and pharmaceutical testing.

The business has exposure to Australia and other Asia-Pacific markets, Europe, the Americas and additional international jurisdictions. Demand for its services reflects customers’ testing volumes, regulatory requirements, project activity and the need for reliable analytical results. Investment in specialist laboratories and instruments supports processing capacity but also creates ongoing maintenance and staffing requirements.

Recent Development

In May 2026, ALS Limited (ASX:ALQ) released its FY26 results for the year ended 31 March 2026. Commodities organic revenue growth was 18.1%, supported by increased mineral exploration activity. Management reported that capacity investments helped accommodate higher sample volumes, while pricing conditions improved during the second half.

The Life Sciences division recorded a more varied operating picture. Food organic revenue increased 7.2%, particularly across European and Asian markets. Environmental trading was softer in the Americas, with the company identifying market conditions, project deferrals and operational factors. Pharmaceutical organic revenue declined 1.6%, while restructuring and efficiency measures continued across the division.

ALS also identified four hub-laboratory projects as part of its capacity investment program. Its published financial calendar places the H1 FY27 results announcement in November 2026, following the half-year end on 30 September 2026.

Financial Performance and Sector Context

ALS Limited (ASX:ALQ) reported FY26 revenue of AUD 3,320.1mn, compared with AUD 2,999.4mn in FY25, an increase of 10.7% YoY. Underlying EBIT rose 19.3% YoY to AUD 599.0mn from AUD 502.3mn, while the underlying EBIT margin increased to 18.0% from 16.7%. Underlying NPAT increased 25.8% to AUD 381.2mn, and statutory NPAT advanced 24.4% to AUD 318.7mn.

The Commodities division generated revenue of AUD 1,294.2mn, up 18.8% YoY, and underlying EBIT of AUD 381.5mn, up 25.9%. The division’s EBIT margin increased to 29.5%. Life Sciences revenue was AUD 2,025.9mn, up 6.0%, with underlying EBIT rising 10.2% to AUD 296.5mn. Its EBIT margin reached 14.6%, compared with 14.1% in FY25.

FY26 free cash flow was AUD 674.1mn, compared with AUD 590.6mn in FY25. Net debt declined from AUD 1,424.1mn to AUD 1,069.5mn. The balance-sheet movement followed the company’s equity raising and cash generation during the year. In its end markets, exploration budgets, environmental regulation, food-testing demand and pharmaceutical development activity influence laboratory utilisation, while currencies affect reported international earnings.

Risks to Consider

ALS Limited (ASX:ALQ) is exposed to changes in mineral exploration spending and customer testing requirements. The Environmental business faces regional demand fluctuations and execution challenges associated with integration and quality improvements. Laboratory expansion involves capital expenditure and the risk that sample volumes develop more slowly than capacity. Currency movements, staffing costs and competition can also affect divisional margins and cash generation.

What to Watch Next

Investors following ALS Limited (ASX:ALQ) can monitor the H1 FY27 result, scheduled for November 2026, for changes in Commodities sample volumes, Life Sciences organic growth and divisional profitability. Other relevant developments include progress on hub-laboratory projects, the Environmental business’s remediation measures, pharmaceutical operations and the company’s net debt and cash conversion. These disclosures will provide a clearer view of operating conditions in the new financial year.

Key Insights

ALS Limited (ASX:ALQ) recorded higher FY26 revenue, underlying earnings and statutory profit, supported particularly by Commodities testing. Life Sciences grew more slowly and contained uneven performance across its markets. The next reporting period will show whether testing activity, cost management and capacity investment continue to translate into operating earnings and cash flow.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.